Cinnarizine in migraine prophylaxis: Efficacy, tolerability and predictive factors for therapeutic responsiveness. An open-label pilot trial

Paolo Rossi, Giancarlo Fiermonte, Francesco Pierelli

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The efficacy and tolerability of cinnarizine (75 mg, at bedtime) in migraine prophylaxis and the presence of possible predictive factors for therapeutic responsiveness were evaluated in an open-label pilot trial. Eighty consecutive outpatients suffering from migraine with or without aura participated in the study. After 12 weeks of therapy, 55 patients experienced a greater than 66% reduction in headache frequency and were considered responders. A significant reduction in the number of migraine days (mean reduction 58±8%) and in intake of medication to treat acute attacks (mean reduction 55±11%) was also observed. Cinnarizine was well tolerated, as documented by the low number of adverse effects. Failure to respond to previous prophylactic treatments was a negative predictive factor correlated with a poor prognosis. This study, even bearing in mind its limitations as an open-label trial, suggests that cinnarizine might be an effective prophylactic anti-migraine agent. The clinical characteristics of migraine patients do not help to predict response to treatment.

Original languageEnglish
Pages (from-to)155-159
Number of pages5
JournalFunctional Neurology
Volume18
Issue number3
Publication statusPublished - Jul 2003

Fingerprint

Cinnarizine
Migraine Disorders
Migraine without Aura
Migraine with Aura
Therapeutics
Headache
Outpatients

Keywords

  • Cinnarizine
  • Migraine
  • Prophylaxis
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Cinnarizine in migraine prophylaxis : Efficacy, tolerability and predictive factors for therapeutic responsiveness. An open-label pilot trial. / Rossi, Paolo; Fiermonte, Giancarlo; Pierelli, Francesco.

In: Functional Neurology, Vol. 18, No. 3, 07.2003, p. 155-159.

Research output: Contribution to journalArticle

@article{080f48cd54d04fb69f73626cae717691,
title = "Cinnarizine in migraine prophylaxis: Efficacy, tolerability and predictive factors for therapeutic responsiveness. An open-label pilot trial",
abstract = "The efficacy and tolerability of cinnarizine (75 mg, at bedtime) in migraine prophylaxis and the presence of possible predictive factors for therapeutic responsiveness were evaluated in an open-label pilot trial. Eighty consecutive outpatients suffering from migraine with or without aura participated in the study. After 12 weeks of therapy, 55 patients experienced a greater than 66{\%} reduction in headache frequency and were considered responders. A significant reduction in the number of migraine days (mean reduction 58±8{\%}) and in intake of medication to treat acute attacks (mean reduction 55±11{\%}) was also observed. Cinnarizine was well tolerated, as documented by the low number of adverse effects. Failure to respond to previous prophylactic treatments was a negative predictive factor correlated with a poor prognosis. This study, even bearing in mind its limitations as an open-label trial, suggests that cinnarizine might be an effective prophylactic anti-migraine agent. The clinical characteristics of migraine patients do not help to predict response to treatment.",
keywords = "Cinnarizine, Migraine, Prophylaxis, Treatment",
author = "Paolo Rossi and Giancarlo Fiermonte and Francesco Pierelli",
year = "2003",
month = "7",
language = "English",
volume = "18",
pages = "155--159",
journal = "Functional Neurology",
issn = "0393-5264",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "3",

}

TY - JOUR

T1 - Cinnarizine in migraine prophylaxis

T2 - Efficacy, tolerability and predictive factors for therapeutic responsiveness. An open-label pilot trial

AU - Rossi, Paolo

AU - Fiermonte, Giancarlo

AU - Pierelli, Francesco

PY - 2003/7

Y1 - 2003/7

N2 - The efficacy and tolerability of cinnarizine (75 mg, at bedtime) in migraine prophylaxis and the presence of possible predictive factors for therapeutic responsiveness were evaluated in an open-label pilot trial. Eighty consecutive outpatients suffering from migraine with or without aura participated in the study. After 12 weeks of therapy, 55 patients experienced a greater than 66% reduction in headache frequency and were considered responders. A significant reduction in the number of migraine days (mean reduction 58±8%) and in intake of medication to treat acute attacks (mean reduction 55±11%) was also observed. Cinnarizine was well tolerated, as documented by the low number of adverse effects. Failure to respond to previous prophylactic treatments was a negative predictive factor correlated with a poor prognosis. This study, even bearing in mind its limitations as an open-label trial, suggests that cinnarizine might be an effective prophylactic anti-migraine agent. The clinical characteristics of migraine patients do not help to predict response to treatment.

AB - The efficacy and tolerability of cinnarizine (75 mg, at bedtime) in migraine prophylaxis and the presence of possible predictive factors for therapeutic responsiveness were evaluated in an open-label pilot trial. Eighty consecutive outpatients suffering from migraine with or without aura participated in the study. After 12 weeks of therapy, 55 patients experienced a greater than 66% reduction in headache frequency and were considered responders. A significant reduction in the number of migraine days (mean reduction 58±8%) and in intake of medication to treat acute attacks (mean reduction 55±11%) was also observed. Cinnarizine was well tolerated, as documented by the low number of adverse effects. Failure to respond to previous prophylactic treatments was a negative predictive factor correlated with a poor prognosis. This study, even bearing in mind its limitations as an open-label trial, suggests that cinnarizine might be an effective prophylactic anti-migraine agent. The clinical characteristics of migraine patients do not help to predict response to treatment.

KW - Cinnarizine

KW - Migraine

KW - Prophylaxis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0346873980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346873980&partnerID=8YFLogxK

M3 - Article

C2 - 14703897

AN - SCOPUS:0346873980

VL - 18

SP - 155

EP - 159

JO - Functional Neurology

JF - Functional Neurology

SN - 0393-5264

IS - 3

ER -